Crescent Biopharma Inc (CBIO) Stock Price, Quote & News

Company Profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 460 5595

Website: crescentbiopharma.com

Address:

300 Fifth Avenue, Waltham, United States

Jt11111 Apr. 14 at 7:33 PM

$CBIO liking this a lot!

0 · Reply

Stonski Apr. 7 at 8:51 PM

$QNCX can we stop with the space X NONSENSE GUYS 😭😭 .. this is gonna be $CBIO 2.0 it’s gonna be a biotech company that takes over the ticker As for why it’s mooning today my guess will be the clean up of the financials ( debt free rn) n talks are heating up

0 · Reply

lyonsa14 Apr. 1 at 11:01 PM

$CBIO Or, may be discussions regarding M&A. I suspect it’s either this or early data results are leaking out. This is just speculation.

0 · Reply

lyonsa14 Apr. 1 at 8:02 PM

$CBIO Just speculation, but likely insiders are seeing early data that looks promising. This is just a guess based on the rapid recent stock price increase. It’s more than obvious that it’s not a level playing field for small retail investors. Biotech investing is very difficult.

0 · Reply

SSRbenny Apr. 1 at 2:41 PM

$CBIO we had insiders loading up or what’s the deal here?

0 · Reply

SonOfOdinX Mar. 31 at 1:37 AM

$CBIO on watch

0 · Reply

topstockalerts Mar. 30 at 6:00 PM

$CBIO this is the kind of action that builds confidence for buyers

0 · Reply

Wallstreetiscriminal Mar. 26 at 7:58 PM

$CBIO @ Billy Peters are you looking at the perceived increase that was actually the RS that took place several months back? I don’t recall a 500% increase just losses from a RS

0 · Reply

slick3333 Mar. 19 at 1:34 AM

$CBIO a bottomless pit coming to a stick near you

0 · Reply

CantNameThatTune Mar. 5 at 11:40 AM

$IBO Thinking about $CBIO that went up 500%+ recently. It was touted for its advancements with its EpiGen CHD and Precision CHD AI driven something or other for which they have yet to generate a single dollar of sales. On this side you have IBO merging with Dr. Ashley Medicine that is currently producing/administering 300 million doses per year for various orphan diseases and CDMOs. I would have thought $BILLIONS in sales would make a stock go higher more than a company with no sales.

0 · Reply

Crescent Biopharma Announces Grants of Inducement Awards

Feb 26, 2026, 7:30 AM EST - 6 weeks ago

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 23, 2026, 7:30 AM EST - 7 weeks ago

Crescent Biopharma to Present at March Investor Conferences

Feb 18, 2026, 7:30 AM EST - 7 weeks ago

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

Feb 5, 2026, 7:30 AM EST - 2 months ago

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 5, 2026, 7:00 AM EST - 3 months ago

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

Dec 4, 2025, 6:35 AM EST - 4 months ago

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

Dec 4, 2025, 6:30 AM EST - 4 months ago

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Nov 6, 2025, 7:30 AM EST - 5 months ago

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 5, 2025, 7:30 AM EST - 5 months ago

Crescent Biopharma to Present at November Investor Conferences

Nov 4, 2025, 9:05 AM EST - 5 months ago

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Aug 28, 2025, 7:30 AM EDT - 8 months ago

Crescent Biopharma to Present at September Investor Conferences

Jul 31, 2025, 7:34 AM EDT - 9 months ago

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 8, 2025, 7:30 AM EDT - 10 months ago

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Jun 16, 2025, 7:00 AM EDT - 10 months ago

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Jun 5, 2025, 4:01 PM EDT - 11 months ago

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

May 29, 2025, 7:30 AM EDT - 11 months ago

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

May 16, 2025, 1:55 PM EDT - 11 months ago

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints David Lubner to Board of Directors

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Mar 5, 2025, 11:20 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

CMRX

Feb 26, 2025, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Nov 12, 2024, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

Oct 29, 2024, 11:47 AM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

PFIE

Oct 29, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Oct 29, 2024, 6:30 AM EDT - 1 year ago

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Jul 25, 2024, 9:00 AM EDT - 1 year ago

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

$GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

Jun 4, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

$GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024$

May 29, 2024, 4:01 PM EDT - 2 years ago

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

$GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

May 6, 2024, 6:00 AM EDT - 2 years ago

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Apr 25, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

Mar 27, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Mar 13, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

Feb 26, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

Feb 12, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jan 4, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Dec 10, 2023, 12:00 PM EST - 2 years ago

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Nov 9, 2023, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

Nov 3, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Oct 30, 2023, 12:00 PM EDT - 2 years ago

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

Oct 20, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

Sep 6, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

Sep 5, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 2, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

Jul 21, 2023, 6:18 PM EDT - 2 years ago

CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO

Jul 19, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023

Jt11111 Apr. 14 at 7:33 PM

$CBIO liking this a lot!

0 · Reply

Stonski Apr. 7 at 8:51 PM

0 · Reply

lyonsa14 Apr. 1 at 11:01 PM

$CBIO Or, may be discussions regarding M&A. I suspect it’s either this or early data results are leaking out. This is just speculation.

0 · Reply

lyonsa14 Apr. 1 at 8:02 PM

0 · Reply

SSRbenny Apr. 1 at 2:41 PM

$CBIO we had insiders loading up or what’s the deal here?

0 · Reply

SonOfOdinX Mar. 31 at 1:37 AM

$CBIO on watch

0 · Reply

topstockalerts Mar. 30 at 6:00 PM

$CBIO this is the kind of action that builds confidence for buyers

0 · Reply

Wallstreetiscriminal Mar. 26 at 7:58 PM

$CBIO @ Billy Peters are you looking at the perceived increase that was actually the RS that took place several months back? I don’t recall a 500% increase just losses from a RS

0 · Reply

slick3333 Mar. 19 at 1:34 AM

$CBIO a bottomless pit coming to a stick near you

0 · Reply

CantNameThatTune Mar. 5 at 11:40 AM

0 · Reply

Stock__Hunter Feb. 25 at 7:57 PM

$CBIO charts never ever lie, but people on these boards do and it's on purpose to take your money Been OG for 20+ yrs ... seen it all

0 · Reply

slick3333 Feb. 22 at 6:21 PM

$CBIO too much pending and too early on for any significant upside risk reward definitely not here wait for the big dump and dilution and re evaluate

0 · Reply

BillionerOfKing Feb. 21 at 1:58 AM

$CBIO Current Stock Price: $11.63

0 · Reply

GSP Feb. 18 at 6:02 PM

$CBIO getting some volume here.

1 · Reply

BullButter23 Feb. 18 at 12:53 PM

$CBIO 🚀🧨🙌🏼 https://www.benzinga.com/pressreleases/26/02/g50682132/crescent-biopharma-announces-first-patient-dosed-in-ascend-phase-12-clinical-trial-of-cr-001-for-t

0 · Reply

OfficialStocktwitsUser Feb. 17 at 2:47 PM

$CBIO RSI: 16.76, MACD: -0.8087 Vol: 1.69, MA20: 10.56, MA50: 11.65 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Estimize Feb. 16 at 1:03 PM

Wall St is expecting -1.08 EPS for $CBIO Q1 [Reporting 04/30 BMO] http://www.estimize.com/intro/cbio?chart=historical&metric_name=eps&utm_c

0 · Reply

Magic8BallResponse Feb. 13 at 8:43 PM

$CBIO Late to the party and late to the party. Oh and late to the party. Keep an eye on institutions that joined late to the party.

0 · Reply

lyonsa14 Feb. 13 at 8:29 PM

$CBIO My main concern is there are several large pharma companies with similar programs that are in phase 3 development. Since CBIO is only in phase 1 development, I’m concerned they’re a bit late with likely a “me too” drug. I’m less concerned about dilution in the short run since they just raised capital at the end of last year. A key question: are they going to develop this agent in tumor types that the other companies are not currently targeting?

0 · Reply

Magic8BallResponse Feb. 13 at 7:24 PM

$CBIO Trials are expensive.

0 · Reply

slick3333 Feb. 12 at 10:09 PM

$CBIO ouchie wow wow new all time low leggo

1 · Reply

Market Cap	252.44M
Revenue (ttm)	10.84M
Net Income (ttm)	-153.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,420.11%
Debt to Equity Ratio	0.00

Volume	506,095
Avg Vol	214,854
Day's Range	N/A - N/A
Shares Out	13.89M
Stochastic %K	31%
Beta	1.04
Analysts	Strong Sell
Price Target	$29.29